Open access
Sep 2026
Targeting the CAF-LPL-STAT3 axis mitigates osimertinib resistance associated with EGFR downregulation.
BACKGROUND Acquired resistance to osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) arises from both tumor cell-intrinsic pathways and tumor microenvironmental cues. Cancer-associated fibroblasts (CAFs) are critical stromal components that drive therapeutic resistance, yet...
Fei Ye, Jia-Bao Wu, Di Liu et al.
· Cellular Signalling · 0 citations